Mark A. Gallop
Fondateur chez Rubedo Life Sciences, Inc.
Profil
Mark A.
Gallop was the founder of XenoPort, Inc. (founded in 1999) where he held the title of Senior Vice President-Research from 1999 to 2009.
He is also the founder of Rubedo Life Sciences, Inc. (founded in 2018) where he currently holds the title of Chairman, Head-Chemistry & Development.
Dr. Gallop's former job(s) include being the Director & Chief Scientific Officer at BlueLight Therapeutics, Inc. He was also the Senior Director-Combinatorial Chemistry at Affymax Research Institute from 1990 to 1999.
Additionally, he served as the Chief Scientific Officer at Nurix Therapeutics, Inc. In terms of education, Dr. Gallop holds a doctorate degree from the University of Cambridge and an undergraduate degree from Auckland University.
Postes actifs de Mark A. Gallop
| Sociétés | Poste | Début |
|---|---|---|
Rubedo Life Sciences, Inc.
 Rubedo Life Sciences, Inc. Packaged SoftwareTechnology Services Rubedo Life Sciences, Inc. develops intelligent drug platform to design unique, targeted and controlled therapies for age-related diseases. The company was founded by Marco Quarta, Mark Gallop and Julian Klein in 2018 and is headquartered in Silicon Valley, CA. | Fondateur | 01/01/2018 |
Anciens postes connus de Mark A. Gallop
| Sociétés | Poste | Fin |
|---|---|---|
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Corporate Officer/Principal | 01/01/1999 |
BlueLight Therapeutics, Inc.
 BlueLight Therapeutics, Inc. BiotechnologyHealth Technology BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | - |
| NURIX THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | - |
| XENOPORT, INC. | Fondateur | - |
Formation de Mark A. Gallop
| Auckland University | Undergraduate Degree |
| University of Cambridge | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NURIX THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Commercial Services |
BlueLight Therapeutics, Inc.
BlueLight Therapeutics, Inc. BiotechnologyHealth Technology BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
Rubedo Life Sciences, Inc.
Rubedo Life Sciences, Inc. Packaged SoftwareTechnology Services Rubedo Life Sciences, Inc. develops intelligent drug platform to design unique, targeted and controlled therapies for age-related diseases. The company was founded by Marco Quarta, Mark Gallop and Julian Klein in 2018 and is headquartered in Silicon Valley, CA. | Technology Services |
